Skip to main content

Adma Biologics, Inc.

ADMA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001368514

No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.

Q3 2021 vs. Q2 2021

How the institutions holding Adma Biologics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of ADMA: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders9072−18
Shares42.9M41.8M−1.10M (−2.6%)
Value$68.6M$47.3M−$21.3M (−31.1%)

New holders (6)

Institutions that held Adma Biologics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to ADMA in Q3 2021
InstitutionSharesValue% of portfolio
Telemetry Investments, L.L.C.60,000$68.0K0.09%
Newbridge Financial Services Group, Inc.46,050$52.0K0.03%
Credit Suisse AG35,000$40.0K0.00%
ExodusPoint Capital Management, LP34,697$39.0K0.00%
JustInvest LLC17,630$20.0K0.00%
Independent Advisor Alliance10,193$12.0K0.00%

Sold out (24)

Institutions that held Adma Biologics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.